Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan
Authors:
Open Access
- 26 June 2012
- journal article
- review article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (11) , 2774-2785
Abstract
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increased mortality in cirrhotic patients, those with end-stage liver disease (ESLD) on transplant waiting lists, and, in some studies, posttransplantation patients. Clinical evidence suggests that adding serum sodium to model for ESLD (MELD) scoring identifies patients in greatest need of liver transplantation by improving waiting list mortality prediction. Hyponatremia is also associated with numerous complications in liver disease patients, including severe ascites, hepatic encephalopathy, infectious complications, renal impairment, increased severity of liver disease in cirrhosis, and increased hospital stay and neurologic/infectious complications posttransplant. Vasopressin receptor antagonists, which act to increase free water excretion (aquaresis) and thereby increase serum sodium concentration, have been evaluated in patients with hypervolemic hyponatremia (including cirrhosis and heart failure) and euvolemic hyponatremia (SIADH). Tolvaptan, a selective vasopressin V2-receptor antagonist, is the only oral agent in this class approved for raising sodium levels in hypervolemic and euvolemic hyponatremia. The SALT trials showed that tolvaptan treatment rapidly and effectively resolved hyponatremia in these settings, including cirrhosis, and it has been shown that this agent can be safely and effectively used in long-term treatment. Fluid restriction should be avoided during the first 24 h of treatment to prevent overly rapid correction of hyponatremia, and tolvaptan should not be used in patients who cannot sense/respond to thirst, anuric patients, hypovolemic patients, and/or those requiring urgent intervention to raise serum sodium acutely.Keywords
This publication has 48 references indexed in Scilit:
- Management of hyponatremia: Providing treatment and avoiding harmCleveland Clinic Journal of Medicine, 2010
- Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisJournal of Hepatology, 2010
- Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentrationLiver International, 2010
- Oral Tolvaptan Is Safe and Effective in Chronic HyponatremiaJournal of the American Society of Nephrology, 2010
- Impact of pretransplant hyponatremia on outcome following liver transplantation #Hepatology, 2009
- The Association Between the Serum Sodium Level and the Severity of Complications in Liver CirrhosisThe Korean Journal of Internal Medicine, 2009
- Therapeutic Potential of Vasopressin Receptor AntagonistsDrugs, 2007
- Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of HyponatremiaThe American Journal of Cardiology, 2006
- Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascitesHepatology, 2002
- HyponatremiaNew England Journal of Medicine, 2000